Onl Therapeutics
Biotechnology, 524 S Main St Ste 110, Ann Arbor, Michigan, 48104, United States, 1-10 Employees
Phone Number: 73********
Who is ONL THERAPEUTICS
ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve...
Read More
-
Headquarters: 524 S Main St Ste 110, Ann Arbor, Michigan, 48104, United States
-
Date Founded: 2011
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
David Esposito
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ONL THERAPEUTICS
ONL Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding ONL Therapeutics
Answer: ONL Therapeutics's headquarters are located at 524 S Main St Ste 110, Ann Arbor, Michigan, 48104, United States
Answer: ONL Therapeutics's phone number is 73********
Answer: ONL Therapeutics's official website is https://onltherapeutics.com
Answer: ONL Therapeutics's revenue is $1 Million to $5 Million
Answer: ONL Therapeutics's SIC: 2834
Answer: ONL Therapeutics's NAICS: 325412
Answer: ONL Therapeutics has 1-10 employees
Answer: ONL Therapeutics is in Biotechnology
Answer: ONL Therapeutics contact info: Phone number: 73******** Website: https://onltherapeutics.com
Answer: ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONLs lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month